Reference
Pinkston O, et al. Type and frequency of immune-related adverse reactions in patients treated with pembrolizumab (keytruda), a monoclonal antibody directed against PD-1, in advanced melanoma at a single institution. Arthritis and Rheumatology 68 (Suppl. S10): 1679-1681 abstr. 1340, Oct 2016. Available from: URL: http://do.org/10.1002/art.39977 [abstract] - USA
Rights and permissions
About this article
Cite this article
Pembrolizumab. Reactions Weekly 1635, 240 (2017). https://doi.org/10.1007/s40278-017-25489-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-017-25489-y